Literature DB >> 2577278

RFLP analysis of HLA-DR beta and -DQ beta genes in the Korean patients with insulin-dependent diabetes mellitus.

H K Lee, B D Rhee, C S Koh, H K Min, J S Seo, G R Kim, H Han, S W Park, D S Choi, H J Yoo.   

Abstract

Human genomic DNA samples from 19 Korean patients and 31 controls of known serological DR antigen specificity were studied for insulin-dependent diabetes mellitus (IDDM)-associated variation in HLA-DR beta and -DQ beta restriction fragment length polymorphisms (RFLPs). Genotyping allowed for accurate assignment of HLA-DR types. For HLA-DRw6, a 12kb/DR beta/Taq I fragment was decreased in Korean IDDM (p less than 0.05). However, we could not find an increased frequency of a 12kb/DQ beta/Bam HI fragment or decreased frequency of a 3.7kb/DQ beta/Bam HI fragment in Korean IDDM. These results suggest a possible protective role of the HLA-DRw6 specificity in IDDM, irrespective of ethnic background, the absence of a specific DQ beta RFLP pattern associated with IDDM in Koreans, and the difference of the Korean population in the genetic of IDDM, compared to the Caucasoid population.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577278      PMCID: PMC4534969          DOI: 10.3904/kjim.1989.4.1.1

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  28 in total

1.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

2.  A systematic study of HLA class II-beta DNA restriction fragments in insulin-dependent diabetes mellitus.

Authors:  O Cohen-Haguenauer; E Robbins; C Massart; M Busson; I Deschamps; J Hors; J M Lalouel; J Dausset; D Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

3.  Identification of a polymorphic variant associated with HLA-DQw3 and characterized by specific restriction sites within the DQ beta-chain gene.

Authors:  S J Kim; S L Holbeck; B Nisperos; J A Hansen; H Maeda; G T Nepom
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

4.  DNA restriction fragment length polymorphisms characteristic for Dw subtypes of DR2.

Authors:  M Segall; H Noreen; L Schluender; F H Bach
Journal:  Hum Immunol       Date:  1986-03       Impact factor: 2.850

5.  Insulin-dependent diabetes mellitus: HLA-DR and -DQ genotyping in three ethnic groups.

Authors:  M R Kohonen-Corish; S W Serjeantson; H K Lee; P Zimmet
Journal:  Dis Markers       Date:  1987-09       Impact factor: 3.434

6.  A DR3-related DX alpha gene polymorphism strongly associates with insulin-dependent diabetes mellitus.

Authors:  G A Hitman; J Sachs; P Cassell; J Awad; G F Bottazzo; A C Tarn; G Schwartz; J P Monson; H Festenstein
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

7.  Class II HLA-DC beta-chain DNA restriction fragments differentiate among HLA-DR2 individuals in insulin-dependent diabetes and multiple sclerosis.

Authors:  D Cohen; O Cohen; A Marcadet; C Massart; M Lathrop; I Deschamps; J Hors; E Schuller; J Dausset
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study.

Authors:  P A Morel; J S Dorman; J A Todd; H O McDevitt; M Trucco
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

9.  Insulin-dependent diabetes--associated HLA-D region encoded determinants.

Authors:  F H Bach; S S Rich; J Barbosa; M Segall
Journal:  Hum Immunol       Date:  1985-02       Impact factor: 2.850

10.  HLA-D region beta-chain DNA endonuclease fragments differ between HLA-DR identical healthy and insulin-dependent diabetic individuals.

Authors:  D Owerbach; A Lernmark; P Platz; L P Ryder; L Rask; P A Peterson; J Ludvigsson
Journal:  Nature       Date:  1983-06-30       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.